Viral specific T cell therapy in kidney transplant recipients - A single-center experience.

Background: Viral infections such as adenovirus (ADV), BK virus (BKV), and cytomegalovirus (CMV) after kidney transplantation negatively impact outcomes in transplant recipients despite advancements in screening and antiviral therapy. We describe our experience of using the virus-specific T cell therapy (VSTs) in kidney transplant recipients (KTR) at our transplant center.

Methods: This is a retrospective, single center review of KTR with ADV, BKV and CMV infections between June 2021 and December 2022.